German biotech Evotec (EVT: Xetra) has bought Seattle, USA-based Just Biotherapeutics for up to $90 million, including performance-based payments over the next three years. The initial consideration upon closing is $60 million.
Evotec, which is currently diversifying into biologics, said the move would offer “considerable business opportunities for further acceleration” of its long-term strategy. The firm is seeking to become “the industry partner of choice for external end-to-end innovation.”
The Hamburg-based firm has inked a number of deals in recent months, including an expanded partnership with Celgene (Nasdaq: CELG) and a dermatologicals deal with Denmark’s LEO Pharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze